公开(公告)号：US20230357378A1

公开(公告)日：2023-11-09

申请号：US18301803

申请日：2023-04-17

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P25/02

CPC classification number: C07K16/24 ,  A61P25/02 ,  A61K45/06

Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

公开(公告)号：US20200157202A1

公开(公告)日：2020-05-21

申请号：US16626630

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

公开(公告)号：US20240360209A1

公开(公告)日：2024-10-31

申请号：US18623647

申请日：2024-04-01

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07K16/24 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20240182555A1

公开(公告)日：2024-06-06

申请号：US18360143

申请日：2023-07-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24

CPC classification number: C07K16/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

公开(公告)号：US20220073601A1

公开(公告)日：2022-03-10

申请号：US17475214

申请日：2021-09-14

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Jae-Keun LEE ,  Dong Sik KIM

IPC: C07K16/24 ,  G01N33/68

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.

公开(公告)号：US20230348584A1

公开(公告)日：2023-11-02

申请号：US18158259

申请日：2023-01-23

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Eun Bee CHO ,  Dong Sik KIM ,  Jae-Keun LEE ,  Soon-gu KWON ,  Jae Young SEONG ,  Juwon SHIM ,  Tae Woo KIM ,  Shin-hyuk KANG

IPC: C07K16/24 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/24 ,  A61P35/00 ,  C07K16/30 ,  A61K45/06

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

公开(公告)号：US20220064277A1

公开(公告)日：2022-03-03

申请号：US17418681

申请日：2019-12-26

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Jae-Keun LEE ,  Juwon SHIM

IPC: C07K16/24 ,  A61P9/10

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

公开(公告)号：US20200299373A1

公开(公告)日：2020-09-24

申请号：US16626624

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd. ,  Seoul National University R&DB Foundation

Inventor： Bongcheol KIM ,  Jae-Keun LEE ,  Dong Sik KIM ,  Junho CHUNG ,  Junyeong JIN

IPC: C07K16/24 ,  A61P35/00 ,  G01N33/574 ,  G01N33/50

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.

公开(公告)号：US20190300599A1

公开(公告)日：2019-10-03

申请号：US16348058

申请日：2017-11-07

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Jae Young SEONG ,  Jong Ik HWANG ,  Eun Bee CHO ,  Junho CHUNG ,  Junyeong JIN ,  Tae Young YUNE ,  Jee Youn LEE

IPC: C07K16/18 ,  G01N33/563

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20230287096A1

公开(公告)日：2023-09-14

申请号：US18177334

申请日：2023-03-02

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Jae-Keun LEE ,  Dong Sik KIM ,  Junho CHUNG ,  Junyeong JIN

IPC: C07K16/24 ,  A61P35/00 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07K16/24 ,  A61P35/00 ,  G01N33/5058 ,  G01N33/57407 ,  A61K2039/505

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.